SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies
February 09, 2015
Based in Dijon, France, the Center will boast a unique offering for drug discovery in Europe, combining Inventiva’s screening platforms and libraries with SensiQ’s instrumentation
Oklahoma City, United States and Dijon, France, February 9, 2015 – SensiQ, a leader in surface plasmon resonance (SPR) technologies and Inventiva, a French drug discovery company focused on therapeutic approaches involving transcription factors and epigenetic targets, today announce the launch of a European Center of Excellence in SPR technologies, using SensiQ® Pioneer Fragment Edition (Pioneer FE) instrumentation.
The SPR Center of Excellence is based in Dijon, France. Inventiva’s existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva’s current service offering. The new Center also allows SensiQ to offer prospective customers on-site demonstrations at Inventiva’s offices. Inventiva’s entire team will benefit from the extensive SPR experience from the SensiQ dedicated support staff.
“The Center of Excellence will provide additional technological capabilities to our partners. It also enhances our extensive HTS and HCS screening platforms, which, combined with our proprietary library, provide one of the most compelling offerings available on the market”, said Frederic Cren, co-founder and CEO of Inventiva. “We look forward to using the SensiQ Pioneer equipment. It provides us with a powerful tool to measure binding interactions and accelerate drug discovery for our partners”, said Pierre Broqua, co-founder and CSO of Inventiva.
“The newly released Pioneer FE represents a new paradigm in capability and performance. We are thrilled that Inventiva has chosen to make it the centerpiece of the SPR Center of Excellence in Dijon”, said Colin Cumming, CEO of SensiQ.
About SensiQ Technologies
SensiQ Technologies is a provider of bioinstrumentation to accelerate drug discovery and development. These systems provide real-time, label-free analysis of biomolecular interactions. SensiQ Technologies products enable robust, rapid, and precise affinity characterization of drug candidates. In particular, the flagship Pioneer FE incorporating the breakthrough OneStep® innovation represents the industry leading instrumentation focused on Fragment Based Drug Discovery. www.sensiqtech.com/products/sensiq-pioneer-fe/
Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.
Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.
Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.
Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management”s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva”s control.
There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.
Please refer to the “Document de référence” filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.
Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.